Analysts See $-0.57 EPS for Sarepta Therapeutics, Inc. (SRPT)

June 15, 2018 - By Larry Purdy

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 0.97 in 2018 Q1. Its down 0.25, from 1.22 in 2017Q4. It worsened, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.
Benchmark Cap Advisors holds 17,250 shares or 1.01% of its portfolio. Nokota Management Limited Partnership has 80,020 shares. Granite Point Capital Mgmt L P owns 31,020 shares for 0.22% of their portfolio. Sg Americas Secs Ltd Liability Company invested 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). The Connecticut-based Wexford Cap Ltd Partnership has invested 0.21% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Zeke Capital Advsrs Limited Liability Co holds 0.02% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 3,249 shares. Td Asset Mgmt Incorporated owns 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 70,900 shares. Atlantic Gp Limited Com owns 9,280 shares or 0% of their US portfolio. Public Employees Retirement Association Of Colorado invested in 0.01% or 10,545 shares. Illinois-based Blair William And Il has invested 0.02% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 24,310 were accumulated by Raymond James Assocs. Dupont Cap owns 5,663 shares for 0.01% of their portfolio. Alps Advsr invested in 86,685 shares. Trexquant Invest L P reported 0.04% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Pnc Fincl Group Inc has invested 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report $-0.57 EPS on July, 18.They anticipate $0.58 EPS change or 50.43 % from last quarter’s $-1.15 EPS. After having $-0.44 EPS previously, Sarepta Therapeutics, Inc.’s analysts see 29.55 % EPS growth. The stock increased 2.08% or $2.01 during the last trading session, reaching $98.78. About 1.65 million shares traded or 32.02% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since June 15, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 16 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 14 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. Sarepta Therapeutics had 27 analyst reports since January 3, 2018 according to SRatingsIntel. Credit Suisse maintained the stock with “Outperform” rating in Friday, May 4 report. The firm has “Hold” rating by Oppenheimer given on Thursday, May 3. SunTrust maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Thursday, March 15. SunTrust has “Buy” rating and $95.0 target. Janney Capital initiated it with “Buy” rating and $75.0 target in Wednesday, January 3 report. The stock has “Equal-Weight” rating by Morgan Stanley on Wednesday, March 21. The rating was initiated by RBC Capital Markets with “Buy” on Monday, January 22. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Overweight” rating by Morgan Stanley on Tuesday, March 6. J.P. Morgan maintained the shares of SRPT in report on Wednesday, February 21 with “Buy” rating. The firm has “Buy” rating by Piper Jaffray given on Friday, March 2. JP Morgan maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Wednesday, March 14. JP Morgan has “Overweight” rating and $95 target.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.47 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Investorplace.com which released: “7 Strong Buy Stocks Analysts Are Upgrading Now, Including Facebook, Inc.” on June 13, 2018, also Nasdaq.com with their article: “Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene …” published on June 13, 2018, Seekingalpha.com published: “EMA’s advisory committee thumbs down on Sarepta’s Exondys” on June 01, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Bizjournals.com and their article: “Biogen’s head of late-stage trials leaves for Sarepta” published on June 07, 2018 as well as Nasdaq.com‘s news article titled: “Sarepta Therapeutics to Present at Two Upcoming Investor Conferences” with publication date: June 05, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.